Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease
Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases, rheumatoid arthritis (RA), and antineutrophil cytoplasmic antibodyassociated vasculitis. Treatment of ILD, mainly based on immunosuppression, remains challenging. Rituximab (RTX), a monoclonal a...
Saved in:
Main Authors: | Caterina Vacchi (Author), Andreina Manfredi (Author), Giulia Cassone (Author), Gian Luca Erre (Author), Carlo Salvarani (Author), Marco Sebastiani (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review
by: Giulia Cassone, et al.
Published: (2021) -
Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications
by: Gian Luca Erre, et al.
Published: (2021) -
Current therapeutic strategies in connective tissue disease-related interstitial lung disease: introduction to the special issue
by: Gian Luca Erre, et al.
Published: (2021) -
Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis
by: Linrui Xu, et al.
Published: (2022) -
Interstitial lung disease in mixed connective tissue disease
by: Marshell Tendean, et al.
Published: (2017)